
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is projected to achieve robust revenue growth, with a 2025 estimate of $5.83 billion, reflecting a 9.2% year-over-year increase, driven significantly by transcatheter aortic valve replacement (TAVR) sales anticipated at $4.27 billion. The company's performance in TAVR is notably strong, with fourth-quarter 2023 sales reaching $1.04 billion, representing a 9.3% year-over-year increase, which surpassed expectations. Additionally, the anticipated growth in the worldwide transcatheter mitral and tricuspid therapies (TMTT) market, expected to expand to $5 billion, further bolsters Edwards Lifesciences's positive outlook in the healthcare sector.
Bears say
Edwards Lifesciences is facing a challenging financial outlook, with management forecasting Q1 2025 growth rates for total company sales and TAVR to fall below the lower bounds of their guidance ranges of 8-10% and 5-7% ex-FX, primarily due to one less selling day in the quarter. Additionally, various revenue growth headwinds, such as macroeconomic factors, slow adoption of TAVR, supply chain disruptions, and increased competition, could impede performance in the coming periods. The anticipated foreign exchange impact on sales could further exacerbate the situation, projected at a $130 million headwind, contributing to an overall negative outlook for the stock.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares